PHARMACOKINETICS AND THERAPEUTIC EFFICACY OF RETINOIDS IN SKIN DISEASES

被引:29
作者
LARSEN, FG
NIELSENKUDSK, F
JAKOBSEN, P
WEISMANN, K
KRAGBALLE, K
机构
[1] MARSELISBORG HOSP,DEPT DERMATOL,AARHUS,DENMARK
[2] AARHUS UNIV,INST PHARMACOL,DK-8000 AARHUS,DENMARK
关键词
D O I
10.2165/00003088-199223010-00004
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The retinoids are a class of compounds that includes the natural forms and synthetic analogues of vitamin A. Isotretinoin, often referred to as a first generation retinoid, may be of considerable benefit to patients with severe, recalcitrant acne. Etretinate and acitretin, 2 aromatic compounds representing the second generation, have found their major success in the treatment of psoriasis, particularly in combination with more traditional therapies. Retinoid therapy is associated with a distinctive adverse effect profile typical of hypervitaminosis A; thus, it is especially important that fertile women undergoing retinoid therapy adhere to a contraceptive regimen. These drugs are extensively metabolised and only traces of unchanged drugs are eliminated in urine. The terminal elimination half-lives of isotretinoin, etretinate and acitretin after long term treatment are up to 20h, 120 days and 48h, respectively. Because of lack of definite correlation between plasma concentration and desired pharmacological effects, in conjunction with the very pronounced inter- and intraindividual variation in systemic availability (15 to 90%) after oral administration of these drugs, initial dosages in individual patients can only be roughly judged on the basis of the general pharmacokinetics of the agents. Later dosage adjustments should be made on the basis of monitoring of both plasma drug (and possible metabolite) concentrations, and the efficacy and tolerability of the drugs.
引用
收藏
页码:42 / 61
页数:20
相关论文
共 100 条
[1]
BENEFIT OF PROGRESSIVELY INCREASING DOSES DURING THE INITIAL TREATMENT WITH ACITRETIN IN PSORIASIS [J].
BERBIS, P ;
GEIGER, JM ;
VAISSE, C ;
ROGNIN, C ;
PRIVAT, Y .
DERMATOLOGICA, 1989, 178 (02) :88-92
[2]
RESIDUAL PLASMA-CONCENTRATIONS OF ACITRETIN (RO-10-1670) AND ITS METABOLITE (RO-13-7652) AFTER CHRONIC ADMINISTRATION [J].
BERBIS, P ;
BUN, H ;
ALMALLAH, NR ;
DURAND, A ;
ROGNIN, C ;
GEIGER, JM ;
PRIVAT, Y .
DERMATOLOGICA, 1988, 177 (04) :244-246
[3]
ACITRETIN (RO10-1670) AND ORAL-CONTRACEPTIVES - INTERACTION STUDY [J].
BERBIS, P ;
BUN, H ;
GEIGER, JM ;
ROGNIN, C ;
DURAND, A ;
SERRADIMIGNI, A ;
HARTMANN, D ;
PRIVAT, Y .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1988, 280 (06) :388-389
[5]
THERAPEUTIC EFFECTS OF AN AROMATIC RETINOIC ACID ANALOG ON CHEMICALLY-INDUCED SKIN PAPILLOMAS AND CARCINOMAS OF MICE [J].
BOLLAG, W .
EUROPEAN JOURNAL OF CANCER, 1974, 10 (11) :731-737
[6]
BOLLAG W, 1984, RETINOID THERAPY REV, P1
[7]
A RAPID AND SIMPLE TEST SYSTEM FOR THE EVALUATION OF THE INHIBITORY ACTIVITY OF RETINOIDS ON INDUCED ORNITHINE DECARBOXYLASE ACTIVITY IN THE HAIRLESS RAT EPIDERMIS [J].
BOUCLIER, M ;
SHROOT, B ;
EUSTACHE, J ;
HENSBY, CN .
JOURNAL OF PHARMACOLOGICAL METHODS, 1986, 16 (02) :151-160
[8]
PHARMACOKINETICS OF ISOTRETINOIN DURING REPETITIVE DOSING TO PATIENTS [J].
BRAZZELL, RK ;
VANE, FM ;
EHMANN, CW ;
COLBURN, WA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (05) :695-702
[9]
BRAZZELL RK, 1982, J AM ACAD DERMATOL, V6, P642
[10]
OVERVIEW OF RECENT CLINICAL PHARMACOKINETIC STUDIES WITH ACITRETIN (RO 10-1670, ETRETIN) [J].
BRINDLEY, CJ .
DERMATOLOGICA, 1989, 178 (02) :79-87